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Abstract. Noggin is an antagonist of bone morphogenetic 
proteins (BMP), being indispensable for certain developmental 
events. The present study aimed to examine the role of Noggin 
in the development and prognosis of gastric cancer (GC) and to 
elucidate the underlying mechanisms. The expression of Noggin 
in GC was evaluated by RT-qPCR, immunohistochemistry and 
by the analyses of publicly available databases. The effects of 
Noggin on proliferation, cell cycle, adhesion, invasion, colony 
formation and tumour spheroid were examined following both 
the knockdown and overexpression of Noggin in GC cell lines. 
The involvement of epidermal growth factor receptor (EGFR) 
signalling was examined by western blot analysis and by using 
small molecule inhibitors. As a result, a higher expression of 
Noggin in GC was found to be associated with a poorer overall 
survival. Noggin overexpression promoted the proliferation and 
colony formation of GC cells by promoting cell cycle progres-
sion. The knockdown of Noggin in HGC27 cells exerted an 
opposite effect on proliferation, colony formation and cell 
cycle progression. Noggin expression positively correlated 
with EGFR expression in both GC cell line models and The 
Cancer Genome Atlas human GC cohort. Targeting EGFR and 
its downstream pathways diminished cell proliferation which 
was promoted by Noggin. Furthermore, Noggin overexpres-
sion resulted in an enhanced nuclear translocation of β-catenin, 
leading to an upregulation of EGFR. Thus, the findings of the 
present study demonstrate that Noggin promotes the prolifera-
tion of GC cells by upregulating EGFR and enhancing a vicious 
circle formed by β-catenin, EGFR, ERK and Akt.
Introduction
Bone morphogenetic proteins (BMPs) are members of the 
transforming growth factor β (TGF-β) superfamily. BMPs play 
a crucial role in the development of diverse tissues and organs, 
such as bone, cartilage, heart and other organs. Previous 
studies have demonstrated that BMPs play an important role 
in the regulation of the homeostasis of the gastric epithelium 
and tumourigenesis (1). As is known, the oxyntic mucosa is 
a complex structure that contains several types of cells, such 
as mucous pit, mucous neck, parietal, zymogenic and endo-
crine cells. BMP-4 has been implicated in the stimulation of 
H+/K+-ATPase α-subunit gene expression and in the promotion 
of secretagogue-stimulated gastric acid production in canine 
parietal cells. These parietal cells may also regulate the process 
of differentiation and development of other cell lineages in the 
gastric mucosa by the production of regulatory factors and 
morphogens (2). The loss of mature parietal cells leads to a 
block in the differentiation program of zymogenic lineages and 
to the development of different types of mucosal cell remodel-
ling. It has therefore been suggested that BMP signalling can 
regulate the homeostasis of the gastric epithelium through its 
ability to control the biological functions of parietal cells (1). 
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The inhibition of BMP signalling in the gastric mucosa causes 
severe abnormalities in the proliferation, maturation and differ-
entiation of several lineages of gastric epithelial cells, forming 
metaplasia, atypical hyperplasia and even tumours (1,3). It 
has been observed that BMP-2 inhibits the growth of gastric 
cancer (GC) cells and that the epigenetic silencing of the 
BMP-2 gene through methylation can be detected in GCs (4). 
Others have also detected a decreased expression of BMP 
signalling molecules in GC (5), which reflects the inhibitory 
effect of BMPs on GC proliferation. In addition, BMPs have 
been associated with the metastasis of GC. The expression of 
BMP‑4 has been found to be significantly higher in gastric 
adenocarcinoma compared to normal mucosa, and BMP-4 
expression has been shown to be inversely associated with the 
prevalence of lymph node metastasis and tumour invasive-
ness (6). BMP-2 staining has been observed more frequently 
in intestinal-type GCs than in diffuse-type, and the expression 
of BMP-2 has been shown to be associated with pathological 
differentiation and lymph node metastasis. In vitro experi-
ments have demonstrated that BMP-2 promotes the metastatic 
potential of GC cells through the phosphoinositide 3-kinase 
(PI3K)/Akt and mitogen-activated protein kinase (MAPK) 
signalling pathways, leading to the activation of nuclear factor 
(NF)-κB and matrix metalloproteinase (MMP)-9 (7).
As a direct antagonist of BMP-2, BMP-4 and BMP-7, 
Noggin can bind to BMPs with high affinity, preventing their 
interaction with BMP receptors and consequently blocking 
downstream signal transduction. Noggin plays a role in both 
normal development and cancer. An elevated Noggin expres-
sion impairs BMP function, contributing to the osteolytic bone 
lesions in breast cancer (8). On the other hand, Noggin can 
potentially be utilised synergistically with receptor activator of 
nuclear factor κB (RANK)/RANK ligand (RANKL)-targeted 
therapy for the treatment of the osteoblastic bone metastases of 
prostate cancer, by reducing BMP-induced osteoblastic activi-
ties (9). Laurila et al examined the expression of Noggin in 
tumour tissues (n=208) of 34 different tumour types by immu-
nohistochemistry (IHC). Among these samples, 8 cases were 
GC specimens. The results revealed that the expression levels 
were weak in 5 cases and 3 cases were moderate, while Noggin 
was expressed at a moderate level in normal gastric tissues (10). 
This  indicates that Noggin may be differentially expressed 
in GCs compared with normal gastric tissues; however,  this 
requires confirmation using a larger number of  GC tissues.
The role of BMPs/Noggin in the development of tumours 
has received increasing attention in recent years and there are 
some indications that it plays an important role in GC; however, 
to date, knowledge of the involvement of BMPs/Noggin in GC 
remains poor. The present study aimed to examine the expres-
sion of Noggin in GC and its involvement in tumourigenesis 
and disease progression. In the present study, Noggin transcript 
levels were determined in a large cohort of 321 GC tissues with 
183 paired adjacent normal gastric tissues. Together with the 
analyses of Noggin expression in The Cancer Genome Atlas 
(TCGA) GC cohort and a cohort of GC data from KMplot, 
a significant association with patient overall survival was 
observed. Finally, in vitro experiments exploring the under-
lying mechanisms of this association revealed that Noggin 
promoted the proliferation of GC cells via the upregulation of 
epidermal growth factor receptor (EGFR).  
Materials and methods
Public gene expression array data. KM plotter analysis 
(http://kmplot.com/) was performed to evaluate the expression 
of Noggin in GC tissues (n=1,065) compared to normal gastric 
tissues (n=57) and its association with the prognosis of patients 
following a previously reported procedure (11).
To identify the clinical significance of Noggin in GC, 
LinkedOmics was adopted, which is constructed based on 
TCGA with 415 cancer samples in the STAD dataset to explore 
the associations between Noggin expression and the patient 
clinicopathological parameters and overall survival (12). 
GC samples. Gastric tumour tissues (n=321) and paired adja-
cent background tissues (n=183) were collected immediately 
following surgery during the period between September, 
2003 to December, 2007 and stored at ‑80˚C until use, 
with written consent from patients at the Peking University 
Cancer Hospital. RNA was isolated and converted into 
cDNA for subsequent quantitative PCR analysis. All protocol 
and procedures of the tissue collection were reviewed and 
approved by Peking University Cancer Hospital Research 
Ethics Committee.
IHC of gastric tissue microarray. Immunohistochemical 
staining was conducted on a gastric adenocarcinoma tissue 
microarray (OD‑CT‑DgStm01‑007, FFPE, formaldehyde‑fixed 
paraffin‑embedded, US Biomax, Inc.) containing 108 cases of 
gastric adenocarcinoma, 10 cases of adjacent normal gastric 
tissue and 10 cases of chronic gastritis. In brief, anti-Noggin 
antibody (sc-16627, 1:50, 1 h at room temperature; Santa Cruz 
Biotechnology Inc.) and a biotinylated secondary antibody 
(1:50, 30 min at room temperature) was used (Vectastain 
Universal Elite ABC kit, PK-6200).
Cell lines and drug treatment. The GC cell lines, MKN7, 
NUGC4, MKN45, HGC27 and AGS, were purchased from 
the American Type Culture Collection (ATCC). Cells were 
routinely cultured at 37˚C, 5% humidified CO2, in Dulbecco's 
modified Eagle medium (DMEM; MAC GENE) supplemented 
with 5% foetal bovine serum (FBS; HyClone; GE Healthcare 
Life Sciences). Gefitinib (ZD1839, Selleckchem), β-catenin 
inhibitor (FH535, Apexbio), Akt inhibitor (MK-2206, 
Selleckchem) and ERK inhibitor (GDC-0994, Selleckchem) 
were employed to verify the involvement of the EGFR, ERK 
and Akt pathways.
RNA extraction and reverse transcription‑PCR (RT‑PCR). 
Total RNA was extracted from confluent cells in a 25 cm2 
flask using the TRI Reagent kit (Sigma‑Aldrich; Merck KGaA 
Inc.). Fresh‑frozen tissues were also first homogenised in the 
TRI reagent followed by RNA extraction. The cDNA was then 
synthesised by RT reaction. The RT reaction was performed 
for 2 µg total using the GoScriptTM Reverse Transcription 
System (Promega Corp.), followed by the amplification of 
Noggin (forward, 5'‑TACAGATGTGGCTGTGGTCG‑3' and 
reverse, 5'‑TGCACTCGGAAATGATGGGG‑3') by PCR. 
GAPDH (forward, 5'‑GGCTGCTTTTAACTCTGGTA‑3' 
and reverse, 5'‑GACTGTGGTCATGAGTCCTT‑3') was 
used as a control.  PCR was carried out using the following 
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conditions, 95˚C for 5 min, followed by 95˚C for 30 sec 
(30 cycles), 55˚C for 30 sec, and 72˚C for 30 sec and a final 
extension of 5 min at 72˚C.
Quantitative PCR (qPCR). cDNA samples from GC 
tissues and cell lines were used for qPCR. qPCR for 
Noggin (forward, 5'‑CAGCGCCTAAGCAAGAAG‑3' and 
reverse, 5'‑ACTGAAGCTGACCGTACAGTCGTTCCA 
CGCGTACAG‑3') and GAPDH (forward, 5'‑ CTGAGTACG 
TCGTGGAGTC‑3'  and reverse, 5'‑ ACTGAACCTGACCGT 
ACACAGAGATGATGACCCTTTTG‑3') was performed 
using the AmpliflourTM UniprimerTM system (InterGen) 
under the following conditions: 94˚C for 10 min, 90 cycles 
of 94˚C for 10 sec, 55˚C for 35 sec, and 72˚C for 20 sec. 
qPCR for p27 (forward, 5'‑CGCCATATTGGGCCACTAA‑3' 
and reverse, 5'‑CGCAGAGCCGTGAGCAA‑3'), cyclin D1 
(forward, 5'‑ GCTCCTGGTGAACAAGCTCAA‑3' and reverse, 
5'‑TTGGAGAGGAAGTGTTCAATGAAA‑3') and GAPDH 
(forward, 5'‑ TGCACCACCAACTGCTTAGC‑3' and reverse, 
5'‑GGCATGGACTGTGGTCATGAG‑3') was performed using 
Power SYBR-Green PCR Master Mix (Applied Biosystems) 
under the following conditions: 94˚C for 2 min and then 40 cycles 
of 94˚C for 15 sec and 55˚C for 1 min. the 2-ΔΔCq (13) method was 
be used for the analysis of the qPCR data.
Western blot analysis. The proteins were extracted using 
lysis buffer and the protein concentration of the cell lysates 
was determined using a DC protein assay kit (Bio-Rad 
Laboratories, Inc.). Protein (20 µg unless specifically stated) 
samples were separated on a SDS‑PAGE gel (10%) and then 
transferred onto PVDF membranes. The blotted membranes 
were incubated at 4˚C overnight with primary antibodies 
(Table SI) and then with corresponding peroxidise-conjugated 
secondary antibodies (1:4,000; Sigma-Aldrich; Merck KGaA 
Inc. cat. no. A5278; A0545 and A5420) at room temperature 
for 1 h. Nuclear proteins were prepared using nuclear isola-
tion buffer (1.58 M sucrose, 40 mM Tris-HCl pH 7.5, 20 mM 
MgCl2, 4% Triton X‑100). Protein bands were visualised 
using enhanced chemiluminescence (EZ-ECL) kit (Biological 
Industries, Israel Beit Haemek Ltd.).
Noggin knockdown and overexpression. Lentiviral 
Noggin shRNA and scramble control were purchased 
from Cyagen Biosciences, Inc. The shRNA sequence 
and negative control were as follows: Noggin sh9, 
GCTAGAGTTCTCCGAGGGCTT; scramble shRNA, 
CCTAAGGTTAAGTCGCCCTCG. Lentiviral particles were 
packaged using 293T cells (ATCC). A total of 2 µg plasmids 
(including 1 µg Noggin shRNA, 0.75 µg pAX2 and 0.25 µg 
pMD2G) and UltraCruz Transfection Reagent (sc 395739; 
Santa Cruz Biotechnology Inc.) was used for transfection. 
The cells were incubated for 72 h and the lentivirus was 
collected. The full-length human Noggin coding sequence 
was amplified from a cDNA library derived from normal 
prostate tissue subject to cloning into a mammalian expres-
sion plasmid vector (pEF6/V5-His TOPO TA plasmid vector, 
Invitrogen, Life Techologies; Thermo Fisher Scientific, Inc.). 
The lentiviral shRNA and Noggin expression plasmid vector 
were used to establish Noggin knockdown and overexpression 
cell lines for the subsequent experiments.  
Cell proliferation assay. Cells were seeded into 96-well plates 
at 3,000 cells per well and incubated at 37˚C with 5% CO2 
for a period up to 120 h. Leica DM IRB microscope (Leica 
Microsystems GmbH) was used to examine the cells. The 
cells were then fixed in 4% formaldehyde and stained with 
0.1% crystal violet (Sigma‑Aldrich; Merck KGaA Inc.). 
Absorbance of the staining was determined at a wave length 
of 540 nm using a spectrophotometer (Elx800, BioTek 
Instruments, Inc.) after the stained crystal violet was dissolved 
with 10% acetic acid. The GraphPad Prism v.6.0 (GraphPad 
Systems Inc.) program was utilized to analyse the data.
Clonogenic assay. A total of 300 cells are seeded in 6-well 
plates and incubated at 37˚C, 5% humidified CO2 for 10 days. 
The cells were then fixed with 4% formalin and stained with 
0.5% crystal violet at room temperature for 15 min. The 
number of colonies was then counted using Leica DM IRB 
microscope (Leica Microsystems GmbH). The GraphPad 
Prism v.6.0 (GraphPad Systems Inc.) program was utilized to 
analyse the data.
Cell adhesion assay. Cell-matrix adhesion was conducted by 
seeding 30,000 cells per well onto a 96-well plate pre-coated 
with Matrigel (BD Biosciences). Non-adherent cells were 
washed off with PBS buffer following 40-min incubation 
at 37˚C, and the remaining adherent cells were fixed with 
4% formalin, stained with 0.5% crystal violet (Sigma‑Aldrich; 
Merck KGaA Inc.) at room temperature for 15 min  and counted 
using a Leica DM IRB microscope (Leica Microsystems 
GmbH). The GraphPad Prism v.6.0 (GradPad Systems Inc.) 
program was utilized to analyse the data. 
Cell invasion assay. Transwell inserts (Greiner Bio-One Ltd.) 
with an 8.0 µm pore size were coated with 50 µg Matrigel and 
air-dried. Following rehydration in BSS buffer, 30,000 cells 
were seeded and incubated  at 37˚C for 72 h. Cells that had 
invaded through the matrix and attached to the other side of the 
bottom membrane were fixed  with 4% formalin and stained 
with 0.5% crystal violet at room temperature for 15 min. The 
invaded cells were destained with acetic acid (10%), and the 
absorbance of the staining was determined at a wave length of 
540 nm using a spectrophotometer (Elx800, BIO-TEK, UK). 
The GraphPad Prism v.6.0 (GraphPad  Systems Inc.) program 
was utilized to analyse the data. 
Cell cycle analysis. Cells were cultured in serum-free medium 
for 36 h to synchronise the cell cycle, which was followed 
by a further 12‑16 h of incubation at 37˚C in medium with 
10% FCS.  Cells were harvested, fixed and stained with 
propidium iodide (PI) (20 µg/ml PI, 2mg/ml RNase A, and 
0.1% Triton X‑100 in phosphate‑buffered saline). DNA content 
was determined with FACSCantoTM II (BD Biosciences). The 
cell cycle was analysed using FCS Express (v4.0, De Novo 
Software).
Statistical analysis. Following a normality check, the t-test was 
employed for normally distributed data, whilst non-normally 
distributed data was analysed using the Mann-Whitney test. 
One-way ANOVA was used for comparisons of continuous 
data between multiple groups, and the Tukey's test was used 
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for further comparisons between groups following ANOVA. 
All experiments were repeated 3 times, and the results are 
expressed as the means ± SD. Differences were considered 
as statistically significant at P<0.05. Data were analysed with 
SPSS software v20 (IBM Corp.). Pearson's correlation coeffi-
cient was applied to test the correlation between two variables. 
Survival analysis was performed using the Kaplan-Meier 
method, and the log-rank test was used to assess statistically 
significant differences.
Results
Higher expression of Noggin in GC is associated with disease 
progression and a poor prognosis. Kaplan-Meier survival 
analyses in both KMplot (Fig. 1A) and the TCGA database 
(Fig. 1B) revealed that patients with a higher expression of 
Noggin in their primary tumour exhibited a poorer overall 
survival than those with a low expression. In the KMplot GC 
cohort, patients with a higher expression exhibited a markedly 
shorter survival (median, 26.3 months) being approximately 
1/3 of that of patients with tumours expressing lower levels of 
Noggin (median, 75.5 months). 
A higher expression of Noggin in the GC tumours was 
also associated with a shorter time to first progression (FP, 
median, 16.1 months, P<0.001) compared with a lower 
expression of Noggin (median, 49.5 months). The associa-
tion between clinicopathological parameters of patients with 
GC and Noggin expression was further analysed using the 
TCGA database and it was found that the expression of 
Noggin was significantly associated with T stage (P<0.05) 
and with M1 (metastatic) disease (P<0.05; Fig. 1C and E). 
However, Noggin expression exhibited no significant asso-
ciation with N staging (Fig. 1D). In contrast to the finding of 
the association of a higher Noggin expression with disease 
progression and a poor prognosis, a decreased expression 
of Noggin in GC was observed in a collective gene expres-
sion array database of GC in which GC tumours (n=1,065) 
exhibited lower Noggin expression levels compared with 
normal gastric tissues (n=57; KMplot) (data not shown). 
Immunochemical staining of Noggin in a gastric tissue 
array (Fig. 1F) and the quantification of Noggin transcripts 
in a cohort of GC by RT-qPCR (Table SII) also revealed 
a decreased expression of Noggin in GC compared with 
adjacent normal gastric tissues. 
Figure 1. A higher Noggin expression is associated with a poorer overall survival of patients with GC. Kaplan-Meier survival analyses revealed associations 
between Noggin expression and the overall survival of patients with GC in both (A) the GC cohort; KMplot (cut-off value was 42) and (B) TCGA data (cut-off 
value was 2.72). Association between Noggin mRNA expression and (C) T stage (n=330), (D) N stage (n=329) and (E) M stage (n=318) of GC in the TCGA cohort. 
(F) Immunohistochemical analysis of Noggin expression in (a) normal tissues and (b) tumor tissues. GC, gastric cancer; TCGA, The Cancer Genome Atlas.
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Noggin promotes proliferation and colony formation of 
GC cells. To explore the cellular machinery underlying the 
role of Noggin in disease progression, the expression of 
Noggin was examined in 5 GC cell lines, including HGC27, 
MKN7, NUGC4, MKN45 and AGS using conventional 
PCR. Noggin expression was detectable in all 5 cell lines, 
while the AGS cell line expressed a relatively lower level 
(Fig. 2A). The knockdown and overexpression of Noggin 
were subsequently established in the HGC27 and AGS cells 
using the lentiviral Noggin shRNA and Noggin overexpres-
sion plasmid vectors, respectively (Fig. 2B). Following 
the knockdown of Noggin, the HGC27 cells exhibited 
a decreased proliferation, while Noggin overexpression 
promoted the proliferation of the AGS cells (Fig. 2C and D). 
Colony formation assays revealed that Noggin overexpres-
sion promoted the proliferation of the AGS cells, while a 
marked decrease in colony numbers was observed in the 
HGC27 cells in which Noggin was knocked down (Fig. 2E). 
The effects of Noggin on the growth of GC cell lines were 
further evaluated using an in vitro 3D spheroid model 
(Fig. 2F and G). The knockdown of Noggin resulted in an 
inhibition of the growth of HGC27 cells (Fig. 2H), whereas 
Noggin overexpression significantly increased the growth 
of AGS cells (Fig. 2I).
Figure 2. Noggin regulates the proliferation and invasion of GC cells. (A) Noggin expression in gastric cancer cell lines at mRNA levels using PCR. (B) Noggin 
knockdown and overexpression in HGC27 and AGS were confirmed by RT‑qPCR and western blot analysis, respectively. Cell proliferation assay was per-
formed on the (C) HGC27NOGsh cells and (D) AGSNOGexp cells. (E) Colony formation assay was performed on the HGC27NOGsh and AGSNOGexp cells. Growth of the 
(F and H) HGC27NOGsh and (G and I) AGSNOGexp cells was examined using a 3D spheroid model. Size of 3-D acini of (H) HGC27NOGsh cells and (I) AGSNOGexp 
cells was determined using ImageJ software. (J) Transwell invasion assay was performed to evaluate the effects of Noggin on the invasiveness of GC cell 
lines. A minimum of 3 independent experiments was performed. Shown are representative experimental data. *P<0.05, **P<0.01 and ***P<0.001 compared to 
the respective control. GC, gastric cancer.
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Noggin promotes the cell cycle of GC cells through the regula‑
tion of cell cycle regulators. The significant effects of Noggin 
on the proliferation of GC cell lines inspired us to further 
explore the underlying cellular events and molecular mecha-
nisms. To explore the molecular mechanisms underlying the 
proliferation-promoting effects of Noggin in GC, the doubling 
time of the HGC27 and AGS cell lines was first calculated. It 
took longer for the cells in which Noggin was knocked down 
to double once, in comparison with the control cells, whilst the 
cells in which Noggin was overexpressed doubled more rapidly, 
with the doubling time being approximately 30% shorter than 
that of the control cells (Fig. 3A). The cell cycle of the HGC27 
and AGS cell lines was further analysed by a flow cytometric 
assay. As shown in Fig. 3B, there was a lower percentage cells 
in which Noggin was knocked down progressing to the S phase 
in the compared to the control, while a greater percentage of 
these cells remained at the G0/G1 phase. Conversely, there was 
a higher percentage of Noggin-overexpressing cells entering the 
G2/M phase and the G0/G1 population of these cells decreased 
compared with the control (Fig. 3C). In addition, the expression 
of cell cycle markers was examined in the AGS cells and HGC27 
cells by RT-qPCR and western blot analysis (Fig. 3D and E). In 
the Noggin-overexpressing AGS cells, the expression levels of 
p21 and p27 were decreased, while those of cMyc and cyclin 
D1 were increased. In contrast to the changes observed in the 
Noggin-overexpressing AGS cells, the HGC27 cells in which 
Noggin was knocked down exhibited an increased expression of 
p21 and p27, and a decreased expression of cMyc and cyclin D1. 
Figure 3. Noggin regulates the cell cycle of GC cells.  (A) Doubling time of HGC27NOGsh and AGSNOGexp cells was calculated based on the proliferation tests. 
(B) Cell cycle analysis showing the automated calculation of different populations allocated at each phase of the cell cycle and the overall percentage of 
cells according to cell cycle phases in the HGC27 cell lines. (C) Effect of Noggin overexpression on the cell cycle of AGSpEF, AGSNOGexp and percentage of 
cells according to cell cycle phases. (D) RT-qPCR was employed to determine the expression of p27 and cyclin D1 in both the HGC27 and AGS cell lines. 
(E) Protein expression of p21, p27, cMyc and cyclin D1 determined by western blot analysis. A minimum of 3 independent experiments was performed. Shown 
are representative experimental data. *P<0.05, **P<0.01 and ***P<0.001 compared to the respective control. GC, gastric cancer.
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Noggin promotes the invasion of GC cells. The effects of 
Noggin on the invasion of GC cell lines were also assessed. 
As shown in Fig. 2J, there was a significantly lower number 
of invading cells in the HGC27NOGsh cells compared with 
the control, and there were much more cells observed on 
the bottom side of the invasion inserts in the AGSNOGexp cells 
in comparison with the control. These findings suggest that 
Noggin promotes the invasion of GC cells.
Noggin overexpression promotes cell proliferation through an 
upregulation of EGFR. There is a close association between 
BMP and EGFR signalling, including their mutual regulation 
of signal transduction and expression of key molecules (14). 
EGFR belongs to the family of receptor tyrosine kinases (RTK) 
ErbB, and it is regarded as an oncogenic factor being over-
expressed in many kinds of cancers, including non-small cell 
lung cancer (15), colorectal cancer (16), pancreatic cancer (17), 
oesophageal cancer (18) and GC as well (19). It has previously 
been found that the overexpression of EGFR increases the 
proliferation of tumour cells through the PI3K/Akt signalling 
pathway (20).  In the present study, the correlation between 
the expression of Noggin and EGFR was first analysed in the 
TCGA GC cohort using gene expression array data. A posi-
tive correlation was observed between Noggin and EGFR 
expression (Pearson's correlation) (Fig. 4A). The expression of 
EGFR and its signalling via ERK and Akt were determined 
by western blot analysis. The upregulation of EGFR and 
the enhanced downstream signalling of both ERK and Akt 
were observed in the AGSNOGexp cells (Fig. 4B). Conversely, 
EGFR expression and activation were almost undetectable 
in the HGC27NOGsh and HGC27SC cells. Higher levels of both 
phosphorylated ERK, Akt and Smad1/5/8 were observed 
Figure 4. EGFR/ERK/Akt in Noggin regulates the proliferation of GC cell lines. (A) Correlation between Noggin and EGFR in the TCGA database. 
(B) Activation of EGFR, ERK and Akt in both HGC27NOGsh and AGSNOGexp cell lines determined by western blot analysis. (C) Involvement of EGFR in the 
Noggin‑promoted proliferation of AGS cells was examined using the EGFR inhibitor, gefitinib. RT‑qPCR was performed to determine the involvement of 
EGFR in the Noggin‑regulated expression of (D) p27 and (E) cyclin D1 following the application of gefitinib (12.5 µmol/l). (F) Corresponding protein expres-
sion was determined by western blot analysis. Cell proliferation assays were performed on AGSNOGexp cells treated with various concentrations of (G) Akt 
inhibitor and (H) ERK inhibitor. Expression of (I) p27 and (J) cyclin D1 in AGSNOGexp cells treated with either AKT inhibitor or ERK inhibitor determined by 
RT-qPCR. A minimum of 3 independent experiments was performed. Shown are representative experimental data. *P<0.05, **P<0.01 and ***P<0.001 compared 
to the respective control. GC, gastric cancer.
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in the HGC27NOGsh cells compared to the control (Fig. 4B). 
The expression of EGFR was analysed at the mRNA level in 
different gastric cancer cell lines in the GSE36139 database, 
and it was found that the expression values of EGFR in the 
HGC27, MKN7, NUGC4, MKN45 and AGS cells were 5.39, 
7.77, 6.64, 6.68 and 6.22, respectively. The HGC27 cells exhib-
ited a lower expression of EGFR than the other 4 GC cell lines 
(data not shown). It was considered that this may be the reason 
for the failure to detect EGFR bands in the HGC27 cell line 
in the western blot analysis experiments in the present study.
To clarify the involvement of EGFR signalling in the 
Noggin-induced increase of the proliferation of AGS cells, 
the EGFR inhibitor, gefitinib, was employed. Treatment with 
gefitinib (12.5 µM, 72 h) led to the concentration‑dependent 
inhibition of the proliferation of AGS cells. The difference 
in the proliferation between the AGSNOGexp and AGSpEF group 
became less significant when the concentration of gefitinib 
was increased to a concentration >12.5 µM (Fig. 4C). Further 
RT-qPCR analysis revealed that the changes in both the expres-
sion of p27 and cyclin D1 in the AGSNOGexp cells were abrogated 
with the addition of gefitinib (Fig. 4D and E). This was further 
supported by the determination of their protein expression by 
western blot analysis (Fig. 4F). Further experiments using small 
inhibitors targeting ERK and Akt revealed that both ERK and 
Akt were involved in the enhanced proliferation induced by 
Noggin-EGFR. Both ERK and Akt inhibitor were able elimi-
nate the promoting effects of Noggin on the proliferation of the 
AGS cells (Fig. 4G and H). Similar to the addition of gefitinib, 
the effect on the cell cycle regulators, including p27 and cyclin 
D1 was also observed in the cells treated with both ERK and 
Akt inhibitor, respectively (Fig. 4I and J).
Noggin overexpression increases EGFR transcription by 
promoting the nuclear translocation of β‑catenin. Previous 
studies have demonstrated that an interaction exists between 
the BMP signalling pathway and the Wnt/β-catenin 
pathway (21,22). The BMP signalling pathway can inhibit 
Wnt/β-catenin signalling via the PTEN/PI3K/Akt pathway (21). 
In addition, EGFR is one of the target genes regulated by 
β-catenin. Therefore, the present study examined the protein 
level nuclear β-catenin in AGS cells by western blot analysis. 
An increase in the levels of nuclear β-catenin was observed in 
the AGSNOGexp cells (Fig. 5A). No obvious change was noted 
for the expression of β-catenin in the total cell lysates. A 
corresponding reduced nuclear β-catenin was observed in the 
HGC27NOGsh cells. Subsequent proliferation assays with the 
Figure 5. Noggin upregulates EGFR in GC cells through an enhanced vicious cycle formed by Akt, ERK, β-catenin and EGFR. (A) Western blot analysis 
was performed to examine β-catenin in both total cell lysates and nuclear protein of AGS and HGC27 compared with controls. (B) Cell proliferation assay 
was performed on AGS cells treated with various concentrations of β-catenin inhibitor. (C) RT-PCR and western blot analysis were performed to determine 
the expression of EGFR in AGSNOGexp cells treated with β-catenin inhibitor in comparison with the vehicle control. (D) Nuclear translocation of β-catenin was 
determined by western blot analysis in AGSNOGexp cells treated with gefitinib, Akt inhibitor or ERK inhibitor for 48 h. A minimum of 3 independent experiments 
was performed. Shown are representative experimental data. **P<0.01 and ***P<0.001. GC, gastric cancer.
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addition of a β-catenin inhibitor revealed an inhibition of the 
proliferation promoted by Noggin overexpression in the AGS 
cells (Fig. 5B).  The addition of β-catenin inhibitor also dimin-
ished the upregulation of EGFR in AGSNOGexp cells which was 
evident at both the mRNA and protein level (Fig. 5C). 
Of note, it was found that the EGFR, Akt and ERK inhibitors 
were able to prevent the Noggin-promoted nuclear translocation 
of  β‑catenin  (Fig. 5D), which was in line with the findings of 
previous studies demonstrating that EGFR-mediated PI3K/Akt 
activation promotes β-catenin transactivation (23,24). As 
shown in Fig. 6A, it is thus suggested that Noggin is able to 
enhance the vicious cycle formed by EGFR and Wnt/β-catenin 
signalling, which reciprocally upregulate each other, ultimately 
leading to an unlimited/deregulated proliferation of GC cells. 
Further Kaplan-Meier survival analyses revealed that a high 
Noggin expression was significantly associated with a poorer 
overall survival of patients with EGFR high-expressing 
tumours (Fig. 6B).
Discussion
To date, knowledge of BMP signalling in GC is extremely 
limited. In the present study, we determined the expression of 
Noggin in human gastric tumour tissues together with paired 
adjacent normal tissues which showed reduced expression of 
Noggin in GCs. This is consistent with the analysis of Noggin 
expression in the TCGA GC cohort and also the IHC staining 
of Noggin in the gastric tissue microarray. Moreover, the 
present study analysed the Noggin promoter methylation status 
in 2 online databases (GSE30601 and TCGA GC) to explore 
the involvement of methylation in the decreased expression of 
Noggin in GC. It was demonstrated that there was an increased 
methylation of the Noggin promoter in gastric tumours 
compared with the paired adjacent normal stomach tissues (data 
not shown). Noggin expression was inversely associated with 
the methylation of Noggin promoter in the TCGA GC cohort 
(data not shown). The exact involvement of this methylation in 
the suppression of Noggin and the mechanisms through which 
it is implicated in tumourigenesis have yet to be elucidated. 
However, the analyses of Noggin expression in GC tumours 
according to their T staging revealed that the invasive, larger 
tumours exhibited a higher expression of Noggin compared 
with smaller tumours confined to the gastric mucosa. Advanced 
tumours with distant metastasis expressed higher levels of 
Noggin compared with localised disease. A significant associa-
tion between a higher expression of Noggin and a shorter survival 
was evident in both the TCGA cohort and KMplot collection. 
Patients with a high Noggin expression in their tumours exhib-
ited a markedly shorter survival, approximately 1/3 of that of 
patients with tumours expressing lower levels of Noggin. This 
suggests that Noggin plays differential roles at different stages 
during tumourigenesis and the disease progression of GC, with 
the survival difference in high Noggin-expressing tumours of 
interest warranting further investigation.
Subsequent experiments revealed a dominating effect of 
Noggin on the cellular functions of GC cells with regard to 
the promotion of proliferation. This was evident in the prolif-
eration assay, colony formation and 3D spheroid growth assay. 
Noggin expression was significantly associated with a shorter 
doubling time of GC cell lines, further supported by the find-
ings in the cell cycle analyses which revealed the promoting 
effect of Noggin on cell cycle progression. Upon binding with 
BMP ligands, BMP receptors activate Smad1/5/8 to form a 
complex with Smad4 followed by nuclear translocation, thus 
regulating BMP responsive genes involved in cellular func-
tions, including proliferation, differentiation, migration and 
invasion. BMP-induced Smad signalling can inhibit the cell 
cycle by increasing the transcription of p21 and p27 (25). 
Figure 6. Noggin-induced vicious cycle and survival of patients with EGFR highly expressing tumours. (A) Enhanced vicious cycle involves Noggin upregula-
tion of EGFR in GC cells. (B) Kaplan-Meier survival analyses demonstrated that high Noggin expression is associated with the poor overall survival of 
patients with high EGFR-expressing tumours. Cut-off values used in the survival analyses were as follows: Median of EGFR, 2.87; median of Noggin, -2.44. 
A minimum of 3 independent experiments was performed. Shown are representative experimental data. GC, gastric cancer.
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Consistent with this, the overexpression of the BMP antagonist, 
Noggin, in the AGS cells, decreased p21 and p27 expression, 
whilst the level of cyclin D1 was increased. Opposite effects 
were observed in the HGC27 cells when Noggin was knocked 
down. 
EGFR belongs to the family of receptor tyrosine kinases 
(RTK) ErbB, and it is overexpressed in numerous types of 
cancer, including non-small cell lung cancer, colorectal cancer, 
pancreatic cancer, oesophageal cancer and GC (15-19). EGFR 
overexpression has been described in 9‑45% of GCs (26‑28), 
while the EGFR gene is amplified in almost 2.3‑16% of GCs 
(26,28). In addition, EGFR mutations have been found in 4% 
of GCs (29).  Increased EGFR signalling is associated with a 
higher stage, a poorly differentiated histology, increased inva-
siveness and a poor prognosis (27,30,31). The known crosstalk 
between BMP and EGFR signalling prompted an exploration 
of the involvement of EGFR in Noggin-promoted proliferation 
and the link with the poorer survival of patients with GC. The 
initial analysis revealed a positive correlation of the expression 
of EGFR and Noggin in the TCGA GC cohort. A previous 
study identified that the overexpression of EGFR increases the 
proliferation of tumour cell through the PI3K/Akt signalling 
pathway (20). EGFR is recognized as an oncogenic driver in 
tumourigenesis and a target for cancer therapy. In the present 
study, further experiments revealed an increased expression of 
EGFR in the AGS cells following the overexpression of Noggin. 
The enhanced activation of corresponding downstream ERK 
and Akt pathways was also evident in the AGSNOGexp cells. 
Experiments were then performed to verify the involvement of 
EGFR signalling in the Noggin-promoted proliferation of GC 
cells. The addition of gefitinib diminished the Noggin‑promoted 
cell proliferation, which was accompanied by an increased 
expression of p21/p27 and a decreased expression of cyclin D1. 
Furthermore, Akt and ERK inhibitors were also able to prevent 
the Noggin-promoted cell proliferation with the corresponding 
changes in the cell cycle regulators. These results demonstrate 
that Noggin promotes the proliferation of GC cells through an 
upregulation of EGFR. The current finding in GC is also in line 
with the role played by Noggin in the regulation of gastric epithe-
lial cells in a murine model. It was previously demonstrated that 
transgenic Noggin overexpression in a mouse model caused the 
activation of the proliferation of gastric epithelial cells through 
an upregulation of EGFR (32). 
Taken together, Noggin can promote the proliferation of GC 
cells collectively through dual mechanisms; the Noggin-induced 
upregulation of EGFR leads to a promotion of proliferation, and 
in addition, the inhibition of proliferation by BMP signalling is 
antagonised by the increased level of Noggin.
It would be of interest to determine the mechanisms 
through which Noggin upregulates the expression level of 
EGFR. Although studies have confirmed the interaction 
between the EGFR pathway and the BMP pathway, the 
majority of studies have focused on the mechanisms through 
which the EGFR/Akt pathway regulates the BMP pathway 
(33,34). To the best of our knowledge, only a few studies to 
date mention that the BMP pathway can also downregulate 
EGFR (35); however, the underlying molecular mechanisms 
remain unclear. Previous studies have demonstrated that there 
is an interaction between the BMP signalling pathway and the 
Wnt/β-catenin pathway (21,36). The BMP signalling pathway 
can inhibit Wnt/β-catenin signalling via the PTEN/PI3K/Akt 
pathway (21). In addition, EGFR is one of the responsive genes 
of β-catenin signalling. Therefore, Noggin could weaken the 
BMP-mediated inhibition of PI3K/Akt pathway signalling, 
leading in turn to enhanced β-catenin signalling. The enhanced 
β-catenin signalling consequently results in the upregulation 
of EGFR. To verify this hypothesis, the nuclear protein level 
of β-catenin was determined in cells in which the expression 
of Noggin was manipulated. An increase in nuclear β-catenin 
expression was observed in the AGSNOGexp cells, while a reduced 
nuclear β-catenin expression was evident in the HGC27NOGSh 
cells. The addition of β-catenin inhibitor diminished the 
upregulation of EGFR induced by Noggin overexpression 
in the AGS cells, as well as the promotion of proliferation. 
These findings indicate that Noggin overexpression increases 
EGFR transcription by promoting the nuclear translocation 
of β-catenin. Moreover, it was found that EGFR, Akt and 
ERK inhibitors also diminished the Noggin-promoted nuclear 
translocation of β-catenin in the Noggin-overexpressing AGS 
cell lines, which was in line with the findings of previous 
studies demonstrating that the EGFR-mediated PI3K/Akt 
activation promotes β-catenin transactivation (23,24). This 
suggests that a reciprocal regulatory network exists among 
among EGFR, BMP and β-catenin signalling, as shown in 
Fig. 6A. BMP plays an inhibitory role in coordinating EGFR 
signalling via the PTEN/PI3K/Akt pathway to limit the nuclear 
translocation of β-catenin, thus regulating EGFR. On the other 
hand, EGFR can also prevent the nuclear translocation of 
Smad signalling complex through the activation of ERK1/2 
(14). This signalling network orchestrates a balanced and 
harmonious response to external stimuli. An elevated Noggin 
expression impairs the balance between EGFR and BMP 
signalling by the increasing the nuclear translocation of 
β-catenin, which consequently enhances the vicious circle 
formed by EGFR/ERK/Akt/β-catenin in GC cells.  Some 
studies have evaluated the efficacy and safety of anti‑EGFR 
drugs, including monoclonal antibodies, such as cetuximab 
and tyrosine kinase inhibitors, such as gefitinib in GC (37‑40). 
Phase II trials combining these agents with cytotoxics in 
unselected patients with GC have yielded high response rates 
between 41 and 65% in the first line setting (37,38). However, 
all of the phase III trials investigating the role of anti-EGFR 
therapy in combination with chemotherapy in GC were 
negative (39,40). The disappointing results of phase III clinical 
trials could be explained by the lack of patient selection for 
those likely to respond to treatment effectively. Therefore, it 
is crucial to further study the molecular mechanisms of GC 
in which EGFR is involved. This will provide a basis for the 
clinical screening of patients who can benefit from anti‑EGFR 
drugs. In the present study, it was found that Noggin promotes 
the proliferation of GC cells mainly through the upregulation 
of EGFR by promoting the nuclear translocation of β-catenin. 
These data suggest that Noggin may be a determining factor 
for the prognosis and therapeutic treatment of EGFR-positive 
gastric tumours. 
Of note, the elevated activation of ERK and Akt was also 
observed in the HGC27 cells in which Noggin was knocked 
down, although by contrast, EGFR was barely detected. 
The expression of EGFR was analysed at the mRNA level 
in different GC cell lines in the GSE36139 database, and it 
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was found that EGFR expression in the HGC27 cell line was 
significantly lower than that of other cell lines (data not shown). 
The reason for this may be the failure to detect EGFR bands in 
the HGC27 cell line in the western blot analysis experiments. 
The elevated activation of ERK and Akt in the HGC27 cells 
in which Noggin was knocked down could be a result of the 
increased Smad-independent signalling of BMP following 
the loss of Noggin. Although some BMPs, such as BMP-10 
can inhibit the proliferation of prostate cancer cells via Smad 
independent signalling (41), there are still many gaps here for 
the knowledge of differences in MAPK pathways triggered by 
different upstream signals, such as EGFR and BMP receptors. 
There are some limitations to the present study. Firstly, 
the knockdown and overexpression of Noggin was established 
in HGC27 and AGS using the lentiviral Noggin shRNA 
and Noggin overexpression plasmid vectors, respectively. 
However, these results need to be verified in other GC cell 
lines. Secondly, the present study did not examine these key 
molecules, such as EGFR in GC specimens to verify the 
underlying mechanisms. These are the directions for further 
research in the future.
In conclusion, a higher expression of Noggin was signifi-
cantly associated with the poorer survival of patients with GC. 
Noggin promotes proliferation of GC cells mainly through the 
upregulation of EGFR by promoting the nuclear translocation 
of β-catenin. An association between a high expression of 
Noggin and a shorter overall survival was evident in tumours 
expressing higher levels of EGFR. Further studies are required 
to elucidate the prognostic and therapeutic potential of this 
molecule in the personalized disease management for GC, 
particularly in EGFR-targeted therapy.
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